



ARZERRA 2009 NET SALES FIGURES

Summary: Net sales of Arzerra™ for the fourth quarter of 2009 were approximately DKK 29 million, with an expected royalty payment to Genmab of DKK 6 million.

Copenhagen, Denmark; February 4, 2010 – Genmab A/S (OMX: GEN) announced today that the U.S. net sales for Arzerra (ofatumumab) during the fourth quarter of 2009 were approximately DKK 29 million (approximately USD 5.5 million). Under the terms of the collaboration with GlaxoSmithKline (GSK), Genmab expects to receive a royalty payment of approximately DKK 6 million (approximately USD 1.1 million).

“We are very pleased to see the first sales figures for Arzerra and we believe that they reflect the need for new treatment options for patients with refractory CLL,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

Arzerra was approved by the FDA in October, 2009, for the treatment of patients in the U.S. with chronic lymphocytic leukemia (CLL) that is refractory to fludarabine and alemtuzumab, and was launched by GSK in mid-November, 2009.

Arzerra is a monoclonal antibody that causes the body’s immune response to fight against normal and cancerous B-cells. Arzerra attaches to the small and large loop epitopes – on a molecule called CD20, which is found on the surface of B-cells, the type of cell that becomes cancerous in CLL.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab’s world class discovery and development teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab’s products and technology, visit www.genmab.com.

This Stock Exchange Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks,

ARZERRA 2009 NET SALES FIGURES

please refer to the section "Risk Management" in Genmab's Annual Report, which is available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Stock Exchange Release nor to confirm such statements in relation to actual results, unless required by law.

Genmab[®]; the Y-shaped Genmab logo[®]; HuMax[®]; HuMax-CD20[®]; HuMax-EGFr[™]; HuMax-IL8[™]; HuMax-TAC[™]; HuMax-HepC[™]; HuMax-CD38[™]; HuMax-CD32b[™]; HuMax-TF[™]; HuMax-Her2[™]; HuMax-VEGF[™] and UniBody[®] are all trademarks of Genmab A/S. Arzerra[™] is a trademark of GlaxoSmithKline.

Contact: Helle Husted, Vice President, Investor Relations
T: +45 33 44 77 30; M: +45 25 27 47 13; E: h.husted@genmab.com

###